A recent Deloitte survey of 120 global healthcare and life sciences executives exposes significant uncertainty stemming from tariffs and pricing policy shifts impacting long-term commercial planning. Most companies are maintaining R&D spending while adjusting sourcing and supply chain strategies. Scenario planning and supply chain bolstering are common, but only a minority have restructured organizations accordingly. The report emphasizes strategic agility is essential to address cumulative operational pressures amid evolving geopolitical and policy landscapes.